All Phenotypes Rnf128<tm1Cdon> MGI Mouse

Phenotypes associated with this allele

Jump to	Allelic Composition	Genetic Background	Genotype ID
hm1	Rnf128^tm1Cdon/Rnf128^tm1Cdon	involves: 129 * C57BL/6	MGI:4459538
hm2	Rnf128^tm1Cdon/Rnf128^tm1Cdon	involves: C57BL/6	MGI:4459533
ht3	Rnf128^tm1Cdon/Rnf128⁺	involves: 129 * C57BL/6	MGI:4459537
cx4	Rnf128^tm1Cdon/Rnf128^tm1Cdon Tg(TcraTcrb)425Cbn/0	involves: 129 * BALB/c * C57BL/6	MGI:4459535
cx5	Foxp3^tm2Ayr/Foxp3⁺ Rnf128^tm1Cdon/Rnf128^tm1Cdon	involves: 129S1/Sv * 129X1/SvJ * C57BL/6	MGI:4459536

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

immune system

increased splenocyte proliferation ( J:160681 )

• splenocytes from ovalbumin primed mice when restimulated with different concentrations of OVA protein fail to exhibit a reduced immune response

• increased in response to MOG peptide restimulation of immunized mice

enlarged spleen ( J:160681 )

• at 18-20 months of age 27 to 50 percent exhibit splenomegaly

• at 26-28 months of age 27 to 75 percent exhibit splenomegaly

increased IgG1 level ( J:160681 )

• slightly elevated anti-OVA IgG1 levels in intranasal immunized asthma model

increased IgM level ( J:160681 )

• anti-OVA IgM increase in intranasal immunized asthma model

abnormal regulatory T cell physiology ( J:160681 )

• reduced suppression of wild-type naive CD4+ T cells when compared with wild-type Treg cells

enlarged mesenteric lymph nodes ( J:160681 )

• beginning at 18 months in some mice

increased interferon-gamma secretion ( J:160681 )

• splenocytes from ovalbumin primed mice when restimulated with different concentrations of OVA protein fail to exhibit a reduced immune response

• by CD4 T cells and by CD4 T cells activated under Th1 and Th17 cell condition

• by CNS infiltrating CD4 T cells in response to MOG peptide immunization

abnormal interleukin secretion ( J:160681 )

• increased interleukin-22 secretion from T cells of ovalbumin primed mice when they are restimulated with OVA

decreased interleukin-13 secretion ( J:160681 )

• T cells from ovalbumin primed mice when they are restimulated with OVA

increased interleukin-17 secretion ( J:160681 )

• by CD4 T cells and by CD4 T cells activated under Th1 and Th17 cell condition

• by CNS infiltrating CD4 T cells in response to MOG peptide immunization

• by T cells from ovalbumin primed mice when restimulated with OVA

increased interleukin-2 secretion ( J:160681 )

• splenocytes from ovalbumin primed mice when restimulated with different concentrations of OVA protein fail to exhibit a reduced immune response

increased interleukin-21 secretion ( J:160681 )

• in T cells from ovalbumin primed mice when they are restimulated with OVA

decreased interleukin-4 secretion ( J:160681 )

• under Th2 cell polarizing conditions

• in splenocytes that are restimulated with Ova peptide

increased interleukin-4 secretion ( J:160681 )

• splenocytes from ovalbumin primed mice when restimulated with different concentrations of OVA protein fail to exhibit a reduced immune response

decreased interleukin-5 secretion ( J:160681 )

• T cells from ovalbumin primed mice when they are restimulated with OVA

abnormal immune tolerance ( J:160681 )

• abnormal oral tolerance in response to secondary ovalbumin exposure

increased susceptibility to experimental autoimmune encephalomyelitis ( J:160681 )

increased anti-double stranded DNA antibody level ( J:160681 )

• at 18-20 months

CNS inflammation ( J:160681 )

• accumulate more CD4+ T cells in the central nervous system (CNS)

lung inflammation ( J:160681 )

• at 18-20 months mononuclear cell infiltration

hematopoietic system

increased splenocyte proliferation ( J:160681 )

• splenocytes from ovalbumin primed mice when restimulated with different concentrations of OVA protein fail to exhibit a reduced immune response

• increased in response to MOG peptide restimulation of immunized mice

enlarged spleen ( J:160681 )

• at 18-20 months of age 27 to 50 percent exhibit splenomegaly

• at 26-28 months of age 27 to 75 percent exhibit splenomegaly

increased IgG1 level ( J:160681 )

• slightly elevated anti-OVA IgG1 levels in intranasal immunized asthma model

increased IgM level ( J:160681 )

• anti-OVA IgM increase in intranasal immunized asthma model

abnormal regulatory T cell physiology ( J:160681 )

• reduced suppression of wild-type naive CD4+ T cells when compared with wild-type Treg cells

respiratory system

lung inflammation ( J:160681 )

• at 18-20 months mononuclear cell infiltration

nervous system

CNS inflammation ( J:160681 )

• accumulate more CD4+ T cells in the central nervous system (CNS)

cellular

increased splenocyte proliferation ( J:160681 )

• splenocytes from ovalbumin primed mice when restimulated with different concentrations of OVA protein fail to exhibit a reduced immune response

• increased in response to MOG peptide restimulation of immunized mice

growth/size/body

enlarged spleen ( J:160681 )

• at 18-20 months of age 27 to 50 percent exhibit splenomegaly

• at 26-28 months of age 27 to 75 percent exhibit splenomegaly

Allelic Composition	Rnf128^tm1Cdon/Rnf128^tm1Cdon
Genetic Background	involves: C57BL/6

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Rnf128^tm1Cdon mutation (0 available); any Rnf128 mutation (10 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

immune system

increased T cell proliferation ( J:160681 )

• nave CD4 T cells when stimulated with anti-CD3 and anti-CD28 compared to wild-type

increased interferon-gamma secretion ( J:160681 )

• by CD4 T cells and nave CD4 T cells when stimulated with anti-CD3 and anti-CD28 compared to wild-type

increased interleukin-17 secretion ( J:160681 )

• by CD4 T cells

increased interleukin-2 secretion ( J:160681 )

• nave CD4 T cells when stimulated with anti-CD3 and anti-CD28 compared to wild-type

increased anti-double stranded DNA antibody level ( J:160681 )

• at 18-20 months

hematopoietic system

increased T cell proliferation ( J:160681 )

• nave CD4 T cells when stimulated with anti-CD3 and anti-CD28 compared to wild-type

cellular

increased T cell proliferation ( J:160681 )

• nave CD4 T cells when stimulated with anti-CD3 and anti-CD28 compared to wild-type

Allelic Composition	Rnf128^tm1Cdon/Rnf128⁺
Genetic Background	involves: 129 * C57BL/6

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Rnf128^tm1Cdon mutation (0 available); any Rnf128 mutation (10 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

immune system

increased susceptibility to experimental autoimmune encephalomyelitis ( J:160681 )

Allelic Composition	Rnf128^tm1Cdon/Rnf128^tm1Cdon Tg(TcraTcrb)425Cbn/0
Genetic Background	involves: 129 * BALB/c * C57BL/6

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Rnf128^tm1Cdon mutation (0 available); any Rnf128 mutation (10 available)
Tg(TcraTcrb)425Cbn mutation (3 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

hematopoietic system

increased splenocyte proliferation ( J:160681 )

• V alpha 2, CD44+ CD4+ T cells from ovalbumin primed mice when stimulated in culture fail to exhibit a reduced immune response

immune system

increased splenocyte proliferation ( J:160681 )

• V alpha 2, CD44+ CD4+ T cells from ovalbumin primed mice when stimulated in culture fail to exhibit a reduced immune response

increased interferon-gamma secretion ( J:160681 )

• V alpha 2, CD44+ CD4+ T cells from ovalbumin primed mice when stimulated in culture fail to exhibit a reduced immune response

increased interleukin-2 secretion ( J:160681 )

• V alpha 2, CD44+ CD4+ T cells from ovalbumin primed mice when stimulated in culture fail to exhibit a reduced immune response

abnormal immune tolerance ( J:160681 )

• abnormal antigen-specific CD4+ T cell tolerance

cellular

increased splenocyte proliferation ( J:160681 )

• V alpha 2, CD44+ CD4+ T cells from ovalbumin primed mice when stimulated in culture fail to exhibit a reduced immune response

Allelic Composition	Foxp3^tm2Ayr/Foxp3⁺ Rnf128^tm1Cdon/Rnf128^tm1Cdon
Genetic Background	involves: 129S1/Sv * 129X1/SvJ * C57BL/6

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Foxp3^tm2Ayr mutation (6 available); any Foxp3 mutation (56 available)
Rnf128^tm1Cdon mutation (0 available); any Rnf128 mutation (10 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

immune system

abnormal regulatory T cell physiology ( J:160681 )

• reduced suppression of wild-type naive CD4+ T cells when compared with wild-type Treg cells

• TGFbeta induced Foxp3-expressing Treg, iTreg, cells have a reduced ability to inhibit the proliferation of nave CD4+ T cells

hematopoietic system

abnormal regulatory T cell physiology ( J:160681 )

• reduced suppression of wild-type naive CD4+ T cells when compared with wild-type Treg cells

• TGFbeta induced Foxp3-expressing Treg, iTreg, cells have a reduced ability to inhibit the proliferation of nave CD4+ T cells

Contributing Projects: Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support.	last database update 06/12/2024 MGI 6.13